Tweets
RT @rheumarampa
"There’s more work to do” as Dr. Floris van Gaalen summarizes the challenges in peripheral SpA
-pSpA has limited lab value testing like imaging, clinical diagnosis
- few clinical trials to support tx guidelines
- SPARTACUS trial: GOL vs. MTX in early pSpA
Dr. John Cush @RheumNow ( View Tweet )
42 minutes 1 second ago
RT @jiharheum
MTX PO split dose MTX (15mg AM + 10mg PM) vs SC in early seropositive #RA in SCOOT RCT (n=252): SC MTX had better EULAR response at 16 wks (OR 0.55, p=0.049) and ↑ transaminitis with oral split. SC MTX remains the preferred route above 15mg/wk. #EULAR2026 OP0206
Dr. John Cush @RheumNow ( View Tweet )
4 hours 11 minutes ago
RT @yuz6yusof
#EULAR2026 OP0337 In double blind LTE WILLOW study, cutaneous efficacy (change in CLASI, CLASI 70/50) was maintained in Enpatoran, TLR 7/8-i by WK48. Those switched from PBO to ENP at WK24 also showed equal efficacy to ENP-ENP group. Promising treatment for #CLE
Dr. John Cush @RheumNow ( View Tweet )
6 hours 11 minutes ago
RT @aurelierheumo
A long release version of xanthine oxidase inhibitor in gout
-442 pts 36 wks
-HR091506 vs febuxostat
-SUA <300 μmol/L: 63.8% vs 40.7% (Δ +22.9%, p<0.0001)
-higher SUA reduction vs baseline
-Similar overall TEAEs (~90%)
A molecule to keep an eye on!
#LB0008
Dr. John Cush @RheumNow ( View Tweet )
7 hours 42 minutes ago
NEW FROM EULAR: A real-world analysis of predictors of IBD in PsA. 🔎 In patients with PsA, signs and symptoms of IBD may appear before diagnosis, but do we know what to look for? Explore the poster: https://t.co/x2pM0T9LWg Sponsored by AbbVie Medical Affairs + Health Impact.
Dr. John Cush @RheumNow ( View Tweet )
9 hours 12 minutes ago
DERM on RheumNow (June 2026)
The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biologics, JAKs - their use, efficacy and side effects. https://t.co/vy4BAx8Lnq
Dr. John Cush @RheumNow ( View Tweet )
23 hours 12 minutes ago
ICYMI: Glucocorticoid Injections in Knee Osteoarthritis
A randomized clinical trial of 60 patients found that glucocorticoid injections into the infrapatellar fat pad (IPFP) did not significantly reduce pain scores in patients with inflammatory knee osteoarthritis (compared to https://t.co/QhW7CMx72x
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
ICYMI: EGPA Review
A current review of eosinophilic granulomatosis with polyangiitis (EGPA) provides current recommendations on diagnosis and management.
https://t.co/rFGoYBMwCP https://t.co/U0HRR7XeVT
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
ICYMI: 2025 Update: EULAR Recommendations on Rheumatoid Arthritis Management
EULAR has updated their rheumatoid arthritis (RA) management recommendations, notably with fewer recommendations (total of 9, down from 11 in 2022 version), by merging and removing previous https://t.co/6WAZB1dOpI
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
ICYMI: B Cells at the Brink in Sjögren Disease
The current issue of Arthritis & Rheumatology reviews current understanding of the immunopathogenesis of Sjögren disease (SjD) and how that has influenced the quest for drug development for this most systemic autoimmune disorder. https://t.co/OBFqHYof5m
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
RT @minidey #OP0342 Interim real-world ASTER data showed anifrolumab improved overall SLEDAI-2K scores & reduced disease activity across multiple organ systems over 12 months, particularly mucocutaneous & MSK domains. Nearly 30% achieved SLEDAI-2K=0 at 1 year. #EULAR2026
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
RT @aurelierheumo Failure to achieve early remission RA asso w/ non-inflammatory pain
NORD-STAR 526 early RA pts)
no remission at 24 wks increased risk of 48wk
• unacceptable pain (OR ~6)
• refractory pain (OR ~6)
• fibromyalgic RA (OR ~16)
Signal strongest w/ very early
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
